Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 3, 2013, Pages 240-246

  Dziewierz, Artur ^a   Siudak, Zbigniew ^a   Rakowski, Tomasz ^a   Kleczyński, Paweł ^a   Dubiel, Jacek S ^a   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Abciximab; Angioplasty; Female; Gender; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; INSULIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EARLY INTERVENTION; FEMALE; GRAFT PATENCY; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; INTRAAORTIC BALLOON PUMP; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS ASPIRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANTIBODIES, MONOCLONAL; EUROPE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; SEX CHARACTERISTICS; TIME FACTORS;

EID: 84884820531     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0826-3     Document Type: Article

References (23)

1. De Luca G, Navarese E, Marino P (2009) Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-regression analysis of randomized trials. Eur Heart J 30:2705-2713
2. Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D (2009) Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1 year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry. Am Heart J 158:569-575
3. Dudek D, Siudak Z, Janzon M, Birkemeyer R, ma Lopez G, Lettieri C, Janus B, Wisniewski A, Berti S, Olivari Z, Rakowski T, Partyka L, Goedicke J, Zmudka K (2008) European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab-EUROTRANSFER Registry. Am Heart J 156:1147-1154
4. Siudak Z, Rakowski T, Dziewierz A, Janzon M, Birkemeyer R, Stefaniak J, Partyka L, Zmudka K, Dudek D (2010) Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol Pol 68:539-543
5. De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, Van'T Hof AW (2008) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart 94:1548-1558
6. Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, Sorysz D, Bryniarski L, Zmudka K, Kaluza GL, Dubiel JS, Dudek D (2007) Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study. Am Heart J 153:360-365
7. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E (2000) TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031-2037
8. D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281
9. Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW (2005) Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 111:1611-1618
10. De Luca G, Suryapranata H, Dambrink JH, Ottervanger JP, Van'T Hof AW, Zijlstra F, Hoorntje JC, Gosselink AT, de Boer MJ (2004) Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: Data from the zwolle myocardial infarction study. Am Heart J 148:852-856
11. De Luca G, Gibson CM, Gyongyosi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, Van'T Hof AW (2010) Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: Insights from the EGYPT cooperation. J Thromb Thrombolysis 30:342-346
12. Tizon-Marcos H, Bertrand OF, Rodes-Cabau J, Larose E, Gaudreault V, Bagur R, Gleeton O, Courtis J, Roy L, Poirier P, Costerousse O, De Larochelliere R (2009) Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes. Am Heart J 157:740-745
13. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van De Werf F, Antman EM, Topol EJ (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA 293:1759-1765
14. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM (2000) Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation in percutaneous transluminal coronary angioplasty to improve long-term outcome with abciximab GP IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stent. J Am Coll Cardiol 36:381-386
15. Mehilli J, Ndrepepa G, Kastrati A, Neumann FJ, Ten BJ, Bruskina O, Dotzer F, Seyfarth M, Pache J, Kufner S, Dirschinger J, Berger PB, Schomig A (2007) Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from intracoronary stenting and antithrombotic regimen: Rapid early action for coronary treatment 2 trial. Am Heart J 154:158-167
16. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218-2230
17. Dziewierz A, Siudak Z, Rakowski T, Chyrchel M, Mielecki W, Janzon M, Birkemeyer R, Tierala I, Wojdyla RM, Dubiel JS, Dudek D (2010) Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in elderly patients transferred with ST-elevation myocardial infarction: Data from the EUROTRANSFER registry. Int J Cardiol 143:147-153
18. Ohlmann P, Reydel P, Jacquemin L, Adnet F, Wolf O, Bartier JC, Weiss A, Lapostolle F, Gaultier C, Salengro E, Benamer H, Guyon P, Chevalier B, Catan S, Ecollan P, Chouihed T, Angioi M, Zupan M, Bronner F, Bareiss P, Steg G, Montalescot G, Monassier JP, Morel O (2012) Prehospital abciximab in ST-segment elevation myocardial infarction: Results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv 5:69-76
19. Van'T Hof AW, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 372:537-546
20. Thiele H, Wohrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: A randomised trial. Lancet 379:923-931
21. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM (2012) Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: The INFUSE-AMI randomized trial. JAMA 307:1817-1826
22. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 373:723-731
23. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131-2141